目的 探讨心宝丸联合瑞舒伐他汀治疗冠心病心绞痛的临床疗效。方法 纳入2022年8月—2025年8月淮南东方医院集团总医院收治的92例冠心病心绞痛患者的病例资料进行回顾性分析，按治疗方案不同分为对照组和治疗组，每组各46例。对照组口服瑞舒伐他汀钙片或瑞舒伐他汀钙胶囊，10 mg/次，每晚固定时间服用1次。在对照组基础上，治疗组口服心宝丸，2丸/次，3次/d，服药时间与瑞舒伐他汀间隔1 h以上。两组疗程均为8周。观察两组临床疗效，比较两组治疗前后心绞痛表现、冠心病心绞痛患者报告临床结局评价量表（CHD-PRO）评分、西雅图心绞痛量表（SAQ）评分、症状自评量表（SCL-90）评分，血小板参数血小板平均体积（MPV）、红细胞分布宽度（RDW）、血小板压积（PCT），及单核细胞与高密度脂蛋白胆固醇比值（MHR）、系统性免疫炎症指数（SII）、全身炎症反应指数（SIRI）水平。结果 治疗后，治疗组总有效率为95.65%，明显高于对照组的80.43%（P＜0.05）。治疗后，两组患者心绞痛NRS评分与发作次数均较治疗前降低，持续时间与硝酸甘油用量均减少（P＜0.05），且治疗组患者心绞痛表现均优于对照组（P＜0.05）。治疗后，两组CHD-PRO、SAQ评分都高于同组治疗前，SCL-90评分都低于同组治疗前（P＜0.05），且治疗组评分均优于对照组（P＜0.05）。治疗后，两组患者MPV、RDW、PCT、MHR、SII和SIRI均较治疗前降低（P＜0.05），同时较之对照组，治疗组治疗后以上指标下降更明显（P＜0.05）。结论 冠心病心绞痛给予心宝丸与瑞舒伐他汀联用治疗，可协同缓解心绞痛症状、减少硝酸甘油用量，在提升生活质量和改善心理状态方面具有优势，并能进一步抑制血小板活化、调节血脂、减轻全身炎症反应，调控疾病多重病理机制，用药安全可靠。

Objective To investigate the clinical efficacy of Xinbao Pills combined with rosuvastatin in the treatment of angina pectoris in patients with coronary heart disease (CHD). Methods Clinical data of 92 patients with CHD-related angina pectoris admitted to Huainan Oriental Hospital Group General Hospital between August 2022 and August 2025 were retrospectively analyzed. According to different therapeutic regimens, the patients were divided into control group and treatment group, with 46 subjects in each group. Patients in the control group received oral rosuvastatin calcium (tablets or capsules) at a dose of 10 mg once every night. On the basis of rosuvastatin therapy, the treatment group was additionally given Xinbao Pills (2 pills, three times daily), with an administration interval of no less than 1 h from rosuvastatin. Both groups were treated for 8 weeks. The clinical efficacy was evaluated. Angina-related manifestations, scores of the Patient-Reported Outcome Scale for Coronary Heart Disease (CHD-PRO), Seattle Angina Questionnaire (SAQ), and Symptom Checklist-90 (SCL-90), platelet-related parameters including mean platelet volume (MPV), red cell distribution width (RDW) and platelet-crit (PCT), as well as monocyte-to-high-density-lipoprotein-cholesterol ratio (MHR), systemic immune-inflammation index (SII) and systemic inflammatory response index (SIRI) were compared before and after treatment between the two groups. Results After intervention, the overall effective rate in the treatment group reached 95.65%, which was significantly higher than 80.43% in the control group (P < 0.05). Both groups exhibited reductions in the numerical rating scale (NRS) score, attack frequency and duration of angina, together with decreased nitroglycerin consumption after treatment (P < 0.05), and these improvements were more pronounced in the treatment group (P < 0.05). Post-treatment CHD-PRO and SAQ scores were elevated, whereas SCL-90 scores declined in both groups relative to baseline (P < 0.05), with superior outcomes observed in the treatment group (P < 0.05). Furthermore, MPV, RDW, PCT, MHR, SII and SIRI were markedly decreased in both groups after treatment (P < 0.05), and the declines of these markers were significantly greater in the treatment group than in the control group (P < 0.05). Conclusion The combined therapy of Xinbao Pills and rosuvastatin exerts synergistic effects in relieving angina symptoms and reducing nitroglycerin requirements for patients with CHD-related angina pectoris. This regimen can improve patients’ quality of life and psychological status, inhibit platelet activation, modulate lipid metabolism and alleviate systemic inflammatory responses by targeting multiple pathological pathways, with favorable safety and reliability for clinical application.

R972

安徽省教育厅科学研究项目（2025AHGXZK30068）